Clicky

Trevi Therapeutics, Inc.(TRVI)

Description: Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.


Keywords: Biopharmaceutical Organic Compounds Organ Systems Chemical Compounds Cough Analgesics Opioids Ethers Idiopathic Pulmonary Fibrosis Nervous System Morphinans Phenols Physiology Pulmonary Fibrosis Dyskinesia Pruritus Levodopa Induced Dyskinesia Parkinson’s Disease Chronic Cough Opioid Receptors Peripheral Nervous System Peripheral Nervous Systems Prurigo Prurigo Nodularis

Home Page: www.trevitherapeutics.com

TRVI Technical Analysis

195 Church Street
New Haven, CT 06510
United States
Phone: 203 304 2499


Officers

Name Title
Ms. Jennifer L. Good Co-Founder, CEO, Pres & Director
Dr. Thomas R. Sciascia M.D. Co-Founder & Chief Science Officer
Ms. Lisa Delfini Chief Financial Officer
Mr. Christopher Galletta Controller & Chief Accounting Officer
Katie McManus Communications Mang.
Mr. Farrell Simon Pharm.D. Sr. VP and Head of Commercial & Strategy
Dr. David J. Clark A.F.P.M., M.D., M.R.C.P. Chief Medical Officer
Ms. Danine Summers VP of Medical Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.2704
Price-to-Sales TTM: 0
IPO Date: 2019-05-07
Fiscal Year End: December
Full Time Employees: 23
Back to stocks